NVX-CoV2515

N/A

Report date: 2022/07/08 22:10:06

Base Information

Drug NameNVX-CoV2515
Drug Alias NameOmicron SARS-CoV-2 rS/Matrix-M AdjuvantOmicron SARS-CoV-2 rS+Matrix-M AdjuvantNVX-CoV2515NVX-CoV-2515
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Biological material > Viral vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesNovavax Inc
China Registration ClassN/A

Develop Information

Active CompaniesNovavax
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A